Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

Palatin achieves patient enrollment target in pivotal phase 3 studies of bremelanotide for FSD treatment

Palatin achieves patient enrollment target in pivotal phase 3 studies of bremelanotide for FSD treatment

Novel antidepressant appears to be safe, effective against depression in clinical trial

Novel antidepressant appears to be safe, effective against depression in clinical trial

UVA opens clinical trial to examine non-surgical treatment for lower urinary tract symptoms

UVA opens clinical trial to examine non-surgical treatment for lower urinary tract symptoms

Can-Fite BioPharma reports financial results, provides updates on drug development programs

Can-Fite BioPharma reports financial results, provides updates on drug development programs

Multicenter trial compares popular treatments for menopause-related vaginal symptoms

Multicenter trial compares popular treatments for menopause-related vaginal symptoms

Men and women see lasting improvements in sex lives after bariatric surgery

Men and women see lasting improvements in sex lives after bariatric surgery

Sexual dysfunction prevalent among recent combat veterans

Sexual dysfunction prevalent among recent combat veterans

Expert proposes new solution to current gridlock over regulation of dietary supplements

Expert proposes new solution to current gridlock over regulation of dietary supplements

Transition Therapeutics Ireland signs agreement for investigator-led TT701 Phase 2 clinical study

Transition Therapeutics Ireland signs agreement for investigator-led TT701 Phase 2 clinical study

Genetic discovery sheds light on how prostate cancer develops and spreads

Genetic discovery sheds light on how prostate cancer develops and spreads

Can-Fite's CF102 granted Orphan Drug Designation by EMA for treatment of hepatocellular carcinoma

Can-Fite's CF102 granted Orphan Drug Designation by EMA for treatment of hepatocellular carcinoma

Hormonal therapy may protect women's ovaries, increase chances of pregnancy after breast cancer treatment

Hormonal therapy may protect women's ovaries, increase chances of pregnancy after breast cancer treatment

Palatin Technologies reports net loss of $12.1 million for fourth quarter 2015

Palatin Technologies reports net loss of $12.1 million for fourth quarter 2015

Bionomics’ BNC210 Phase 1 trial for anxiety and depression meets primary endpoint

Bionomics’ BNC210 Phase 1 trial for anxiety and depression meets primary endpoint

Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs

Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs

Valeant enters into definitive agreement to acquire Sprout Pharmaceuticals

Valeant enters into definitive agreement to acquire Sprout Pharmaceuticals

S1 Biopharma supports FDA's approval of flibanserin for women living with HSDD

S1 Biopharma supports FDA's approval of flibanserin for women living with HSDD

Palatin applauds FDA's approval of flibanserin for women living with hypoactive sexual desire disorder

Palatin applauds FDA's approval of flibanserin for women living with hypoactive sexual desire disorder

Even the Score issues statement on FDA approval of flibanserin for treatment of women with HSDD

Even the Score issues statement on FDA approval of flibanserin for treatment of women with HSDD

Urologists report success in treating bladder issues, pelvic pain through neuromodulation technique

Urologists report success in treating bladder issues, pelvic pain through neuromodulation technique